Targeting AML through DR4 with a novel variant of rhTRAIL

Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively insensitive to TRAIL-induced apopt...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Cell Mol Med
Egile Nagusiak: Szegezdi, Eva, Reis, Carlos R, van der Sloot, Almer M, Natoni, Alessandro, O’Reilly, Aoife, Reeve, Janice, Cool, Robbert H, O’Dwyer, Michael, Knapper, Steven, Serrano, Luis, Quax, Wim J, Samali, Afshin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2011
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394230/
https://ncbi.nlm.nih.gov/pubmed/21070598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2010.01211.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak